Labcorp
Preço: 266.16Empresa e modelo de negócios
Labcorp is a leading healthcare company that provides comprehensive laboratory services and diagnostic solutions. Its core offerings include clinical laboratory testing, drug development services, and genomic testing. The company operates in two major segments: Labcorp Diagnostics and Labcorp Drug Development. Major revenue sources stem from clinical testing services for healthcare providers and pharmaceutical companies, as well as from its extensive portfolio of laboratory tests and clinical trials.
Perfil de investimento
The investment profile of Labcorp is more aligned with value investors, given its stable revenue generation and modest dividend yield. The stock may appeal to those seeking consistent performance rather than aggressive growth, reflecting a balanced approach to risk and potential returns.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 11.37 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- 0.6% ≈
- Surpresa de EPS
- 3.0% em linha
- Volatilidade 20d
- 1.1% estável
- Dividend yield
- 1.1% moderado última data ex-dividendo: 2026-05-29
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-10 00:48 | Manter | Comprar | Strong performance and solid fundamentals support growth potential. |
| 2026-05-24 02:44 | Vender | Manter | Mixed performance; cautious outlook amid market conditions. |
| 2026-05-16 02:42 | Manter | Vender | Weak momentum and fundamentals raise significant risk. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-05-01 12:49 | Robert W. Baird | Preço-alvo elevado | 332 → 334 | 255.97 |
| 2026-04-08 13:14 | Evercore ISI | Preço-alvo elevado | 280 → 300 | 274.72 |
| 2026-02-24 11:40 | Piper Sandler | Preço-alvo elevado | 270 → 300 | 285.3 |
Nada ainda